Other formats:
BibTeX
LaTeX
RIS
@proceedings{1841043,
author = {Poddubnyy, D. and Deodhar, A. and Baraliakos, X. and Blanco, R. and Dokoupilová, Eva and Hall, S. and Kivitz, A. and Van de Sande, M.G.H. and Stefanska, A. and Pertel, P. and Richards, H. and Braun, J.},
doi = {http://dx.doi.org/10.1136/annrheumdis-2021-eular.143},
keywords = {secukinumab, non-radiographic axial spodyloarthritis},
language = {eng},
title = {SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM THE PREVENT STUDY},
url = {https://ard.bmj.com/content/80/Suppl_1/707.1},
year = {2021}
}
TY - CONF
ID - 1841043
AU - Poddubnyy, D. - Deodhar, A. - Baraliakos, X. - Blanco, R. - Dokoupilová, Eva - Hall, S. - Kivitz, A. - Van de Sande, M.G.H. - Stefanska, A. - Pertel, P. - Richards, H. - Braun, J.
PY - 2021
TI - SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM THE PREVENT STUDY
KW - secukinumab, non-radiographic axial spodyloarthritis
UR - https://ard.bmj.com/content/80/Suppl_1/707.1
N2 - Axial spondyloarthritis (axSpA) is an inflammatory disease characterised by chronic back pain, and it comprises radiographic axSpA and non-radiographic axSpA (nr-axSpA).1 Secukinumab (SEC) 150 mg, with (LD) or without loading (NL), dose significantly improved the signs and symptoms of patients with nr-axSpA in the PREVENT (NCT02696031) study through Week 52.
ER -
PODDUBNYY, D., A. DEODHAR, X. BARALIAKOS, R. BLANCO, Eva DOKOUPILOVÁ, S. HALL, A. KIVITZ, M.G.H. VAN DE SANDE, A. STEFANSKA, P. PERTEL, H. RICHARDS and J. BRAUN. \textit{SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM THE PREVENT STUDY}. 2021. Available from: https://dx.doi.org/10.1136/annrheumdis-2021-eular.143.
|
